Developing and licensing products through mutually beneficial collaborations is one of Emisphere's core business strategies. Emisphere is currently looking for collaborations in licensing Eligen B12™ outside of the US in order to leverage the product.
By working with established biotechnology and pharmaceutical companies, Emisphere can accelerate the availability of the new product to ultimately benefit patients, partners, and shareholders.
Emisphere's capabilities enable it to form strategic partnerships with leading companies, ranging from early stage proof of concept studies to extensive development and commercial collaborations.
For more information on licensing Eligen B12™, please contact: